Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2007, Vol. 110, No. 1, pp. 313-322.
Prepublished online as a Blood First Edition Paper on March 15, 2007; DOI 10.1182/blood-2006-10-050260.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figure
Right arrow All Versions of this Article:
blood-2006-10-050260v1
110/1/313    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carew, J. S.
Right arrow Articles by Cleveland, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carew, J. S.
Right arrow Articles by Cleveland, J. L.
Related Collections
Right arrow Apoptosis
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance

Jennifer S. Carew1, Steffan T. Nawrocki2, Charissa N. Kahue1,3, Hui Zhang4, Chunying Yang1, Linda Chung1, Janet A. Houghton2, Peng Huang4, Francis J. Giles5, and John L. Cleveland1,6

1 Departments of Biochemistry and 2 Oncology, St. Jude Children's Research Hospital, Memphis, TN; 3 Chaminade University, Honolulu, HI; 4 Departments of Molecular Pathology and 5 Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; 6 Department of Cancer Biology, The Scripps Research Institute-Florida, Jupiter

Novel therapeutic strategies are needed to address the emerging problem of imatinib resistance. The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) is being evaluated for imatinib-resistant chronic myelogenous leukemia (CML) and has multiple cellular effects, including the induction of autophagy and apoptosis. Considering that autophagy may promote cancer cell survival, we hypothesized that disrupting autophagy would augment the anticancer activity of SAHA. Here we report that drugs that disrupt the autophagy pathway dramatically augment the antineoplastic effects of SAHA in CML cell lines and primary CML cells expressing wild-type and imatinib-resistant mutant forms of Bcr-Abl, including T315I. This regimen has selectivity for malignant cells and its efficacy was not diminished by impairing p53 function, another contributing factor in imatinib resistance. Disrupting autophagy by chloroquine treatment enhances SAHA-induced superoxide generation, triggers relocalization and marked increases in the lysosomal protease cathepsin D, and reduces the expression of the cathepsin-D substrate thioredoxin. Finally, knockdown of cathepsin D diminishes the potency of this combination, demonstrating its role as a mediator of this therapeutic response. Our data suggest that, when combined with HDAC inhibitors, agents that disrupt autophagy are a promising new strategy to treat imatinib-refractory patients who fail conventional therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. Han, W. Hou, L. A. Goldstein, C. Lu, D. B. Stolz, X.-M. Yin, and H. Rabinowich
Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells
J. Biol. Chem., July 11, 2008; 283(28): 19665 - 19677.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Carew, S. T. Nawrocki, V. K. Reddy, D. Bush, J. E. Rehg, A. Goodwin, J. A. Houghton, R. A. Casero Jr, L. J. Marton, and J. L. Cleveland
The Novel Polyamine Analogue CGC-11093 Enhances the Antimyeloma Activity of Bortezomib
Cancer Res., June 15, 2008; 68(12): 4783 - 4790.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. R. Fantin and V. M. Richon
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. K. Amaravadi and C. B. Thompson
The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment
Clin. Cancer Res., December 15, 2007; 13(24): 7271 - 7279.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020